Departamento de Patología y Laboratorios, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, D.C., Colombia; Departamento de Patología, Facultad de Medicina, Universidad Nacional de Colombia, Bogotá, D.C., Colombia; Pathology Department, McGill University, Montreal, Quebec, Canada.
Servicio de Trasplante Hepático, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, D.C., Colombia.
Biomedica. 2020 Sep 1;40(3):498-506. doi: 10.7705/biomedica.4861.
Introduction: The post-transplant lymphoproliferative disorders (PTLD) are characterized by an uncontrolled pathological lymphoid proliferation as a consequence of transplant immunosuppression therapy. Objective: To characterize the clinical and pathological characteristics of PTLD in a cohort of adult patients with liver transplant during a 15 year period at the Hospital Universitario Fundación Santa Fe de Bogota. Materials and methods: We conducted an observational retrospective study by searching for the PTLD cases diagnosed during the study period in the databases of the Liver Transplantation Unit and the Pathology Department. We collected the epidemiological, clinical, and pathological information and performed the corresponding statistics analyses. Results: During the research period, 572 patients were transplanted; the incidence of PTDL was 2.44%; 79% of them were man and the average age at the time of diagnosis was 62.5 years; 71% of the cases were diagnosed during the first year after the transplant and the same percentage EBV-seropositive patients. The most frequent pathological phenotype was monomorphic and the majority of tumors was detected in the hepatic hilum. The one-year survival was 50%. Conclusion: The high proportion of early cases and the high frequency of Epstein-Barr virus seropositivity both in donors and receptors drewour attention. More studies are necessary to have a better understanding of this condition in Colombia. This is the first PTLD clinical and pathological analysis in liver-transplant patients from Colombia to date.
移植后淋巴组织增生性疾病（PTLD）的特征是由于移植免疫抑制治疗而导致的不受控制的病理性淋巴样增生。目的：在 15 年期间，在波哥大 Santa Fe 基金会大学医院，对一组成年肝移植患者的 PTLD 进行临床和病理特征分析。材料和方法：我们通过在肝移植单位和病理科的数据库中搜索研究期间诊断的 PTLD 病例，进行了一项观察性回顾性研究。我们收集了流行病学、临床和病理信息，并进行了相应的统计分析。结果：在研究期间，572 名患者接受了移植；PTLD 的发病率为 2.44%；其中 79%为男性，诊断时的平均年龄为 62.5 岁；71%的病例在移植后第一年诊断，同样比例的 EBV 血清阳性患者。最常见的病理表型是单形性，大多数肿瘤位于肝门。一年生存率为 50%。结论：早期病例比例高，供体和受体 EBV 血清阳性率均高，这引起了我们的注意。需要更多的研究来更好地了解哥伦比亚的这种情况。这是迄今为止哥伦比亚首例肝移植患者的 PTLD 临床和病理分析。
